12-2019

**Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting**

Alexander B. Ramos

Roberto A. Cruz  
_The University of Texas Rio Grande Valley, roberto.cruzsaldana@utrgv.edu_

Nicole R. Villemarette-Pittman

Piotr W. Olejniczak

Edward C. Mader Jr.

Follow this and additional works at: [https://scholarworks.utrgv.edu/som_pub](https://scholarworks.utrgv.edu/som_pub)

Part of the [Neurology Commons](https://scholarworks.utrgv.edu/som_pub)

**Recommended Citation**

Ramos, A. B., Cruz, R. A., Villemarette-Pittman, N. R., Olejniczak, P. W., & Mader, E. C., Jr (2019). Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting. *Journal of investigative medicine high impact case reports, 7*, 2324709619848816.  
[https://doi.org/10.1177/2324709619848816](https://doi.org/10.1177/2324709619848816)

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [justin.white@utrgv.edu](mailto:justin.white@utrgv.edu), [william.flores01@utrgv.edu](mailto:william.flores01@utrgv.edu).
Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting

Alexander B. Ramos, MD, MS\(^1\), Roberto A. Cruz, MD\(^1\), Nicole R. Villemarette-Pittman, PhD\(^1\), Piotr W. Olejniczak, MD, PhD\(^1\), and Edward C. Mader Jr, MD\(^1\)

Abstract

Refractory seizures or status epilepticus (RS/SE) continues to be a challenge in the inpatient setting. Failure to abort a seizure with antiepileptic drugs (AEDs) may lead to intubation and treatment with general anesthesia exposing patients to complications, extending hospitalization, and increasing the cost of care. Studies have shown a key role of inflammatory mediators in seizure generation and termination. We describe 4 patients with RS/SE that was aborted when dexamethasone was added to conventional AEDs: a 61-year-old female with temporal lobe epilepsy who presented with delirium, nonconvulsive status epilepticus, and oculomotor seizures; a 56-year-old female with history of traumatic left frontal lobe hemorrhage who developed right face and hand epilepsia partialis continua followed by refractory focal clonic seizures; a 51-year-old male with history of traumatic intracranial hemorrhage who exhibited left-sided epilepsia partialis continua; and a 75-year-old female with history of breast cancer who manifested nonconvulsive status epilepticus and refractory focal clonic seizures. All patients continued experiencing RS/SE despite first- and second-line therapy, and one patient continued to experience RS/SE despite third-line therapy. Failure to abort RS/SE with conventional therapy motivated us to administer intravenous dexamethasone. A 10-mg load was given (except in one patient) followed by 4.0- 5.2 mg q6h. All clinical and electrographic seizures stopped 3-4 days after starting dexamethasone. When dexamethasone was discontinued 1-3 days after seizures stopped, all patients remained seizure-free on 2-3 AEDs. The cessation of RS/SE when dexamethasone was added to conventional antiseizure therapy suggests that inflammatory processes are involved in the pathogenesis of RS/SE.

Keywords refractory seizures, status epilepticus, antiepileptic drugs, inflammation, anti-inflammatory, steroid, dexamethasone

Received January 20, 2019. Revised March 27, 2019. Accepted April 2, 2019.

Introduction

Status epilepticus (SE) is defined by the International League against Epilepsy (ILAE) as a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which (after time point \(t_1\)) lead to abnormally prolonged seizures and which (after time point \(t_2\)) result in long-term consequences including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the duration and seizures type.\(^1\)\(^2\) A classification system for SE was recently proposed by the ILAE based on 4 criteria (axes): semiology (Table 1), etiology, age, and electroencephalography (EEG) correlates.\(^1\)

The following information must be included in describing the EEG in SE: (1) spatial distribution: generalized or bisynchronous, lateralized, bilateral independent, multifocal; (2) name of pattern: periodic discharges, rhythmic delta activity, or spike-and-wave/sharp-and-wave plus subtypes; (3) morphology: sharpness, number of phases (eg, triphasic), absolute and relative amplitude, polarity; (4) temporal features:

\(^1\)Louisiana State University Health Sciences Center, New Orleans, LA, USA

Corresponding Author:
Alexander B. Ramos, MD, MS, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, 7th Floor, Room 763, New Orleans, LA 70112, USA.
Email: aramos@lsuhsc.edu

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
onset (sudden vs gradual), prevalence, frequency, duration, daily pattern, dynamics (evolving, fluctuating, or static); (5) modulation: stimulus-induced versus spontaneous; and (6) effects of interventions, such as antiepileptic drug (AED) administration.1,3

Convulsive SE (CSE; A.1.a. in Table 1) is characterized by prolonged (>5 minutes) convulsions, that is, episodes of excessive abnormal muscle contractions, usually bilateral, which may be sustained or interrupted.1,4 The best time point estimates for CSE are: t1 = 5 minutes, t2 = 30 minutes.5 Nonconvulsive SE (NCSE; SE.B category in Table 1) includes all SE subtypes without prominent motor manifestations (Table 1). The best time point estimates for focal NCSE with impaired consciousness (B.2.b.c in Table 1) are: t1 = 10 minutes, t2 = 60 minutes.1 In this article, we will simply refer to the B.2.b.c subtype of NCSE as NCSE. Refractory status epilepticus (RSE) has no universally accepted definition. Some definitions specify a minimum number of AEDs to which SE fails to respond (eg, 2 or 3) or a minimum time over which SE persists despite adequate treatment (eg, 1 or 2 hours).5 A common definition is the following: SE persisting despite adequate treatment (eg, 1 or 2 hours).5 Two types of SE are fundamentally related to a specific type of short-duration seizure.7 While short-duration seizures do not meet the definition of SE, non-SE seizures that frequently occur despite adequate AED treatment may actually need the same treatment as their SE counterparts. We arbitrarily define refractory seizures (RS) as frequently recurring seizures that cannot be controlled with at least one benzodiazepine and at least one non-benzodiazepine AED (same criteria for RSE).

RS or status epilepticus (RS/SE) is a major challenge in the inpatient setting for a number of reasons. First, there is no incontrovertible evidence in humans that all forms of sustained epileptiform activity in the electroencephalogram (EEG) will result in clinically significant brain injury and enduring functional impairment in addition to that which has been caused by the primary brain lesion, systemic disturbances, and medical interventions.5-10 Second, the physiological basis and pathological implications of various scalp EEG patterns remain controversial and it is not always easy to decide where some EEG patterns would lie in the ictal-interictal continuum.11-13 Third, it is not always possible to abort RS/SE with currently available AEDs even when several drugs are combined and administered at maximum (nonanesthetic) doses.14,15 Fourth, aggressive treatment of RS/SE with general anesthesia, intubation, and intensive care unit (ICU) monitoring exposes the patient to the risk of medical complications, increases the cost of health care, and puts a strain on limited hospital resources.16,17 In the United States, patients with RS/SE are often managed in the ICU where continuous EEG (CEEG) monitoring is performed.

SE, notably CSE, is an emergency that must be aborted immediately when encountered in the field, clinic, ambulance, emergency room (ER), or inpatient setting. CSE can be diagnosed clinically whereas NCSE requires EEG confirmation. Because SE can be difficult to abort, physicians who are faced with this challenge must be aware of a few caveats. While it is well known that inducing SE in laboratory animals can cause irreversible brain injury, the results of most animal studies cannot be extrapolated to human SE, particularly NCSE.18-20 Several clinical studies have correlated SE with increased probability of unfavorable functional outcome or death. However, the increase in morbidity

Table 1. Classification of Status Epilepticusa.

| A. With Prominent Motor Symptoms | B. Without Prominent Motor Symptoms (ie, Nonconvulsive SE, NCSE) |
|---------------------------------|---------------------------------------------------------------|
| A.1. Convulsive SE (CSE, synonym: tonic-clonic SE) | B.1. NCSE with coma (including so-called “subtle” SE) |
| A.1.a. Generalized convulsive | B.2.a. Generalized |
| A.1.b. Focal onset evolving into bilateral convulsive SE | B.2.a.a. Typical absence status |
| A.1.c. Unknown whether focal or generalized | B.2.a.b. Atypical absence status |
| A.2. Myoclonic SE (prominent epileptic myoclonic jerks) | B.2.a.c. Myoclonic absence status |
| A.2.a. With coma | B.2.b. Focal |
| A.2.b. Without coma | B.2.b.a. Without impairment of consciousness (aura continua, with autonomic, sensory, visual, olfactory, gustatory, emotional/psychic/experiential, or auditory symptoms) |
| A.2.c. Unknown whether focal or generalized | B.2.b.c. With impaired consciousness |
| A.3. Focal motor | B.2.c. Unknown whether focal or generalized |
| A.3.a. Repeated focal motor seizures (Jacksonian) | B.2.c.a. Autonomic SE |
| A.3.b. Epilepsia partialis continua (EPC) | |
| A.3.c. Adverse status | |
| A.3.d. Oculoclonic status | |
| A.3.e. Ictal paresis (ie, focal inhibitory SE) | |
| A.4. Tonic status | |
| A.5. Hyperkinetic SE | |

Abbreviations: SE, status epilepticus; NCSE, nonconvulsive SE; CSE, convulsive SE; EPC, epilepsy partialis continua.

The table shows axis 1 of the classification of SE as proposed by the International League against Epilepsy Task Force on Classification of SE and published in 2015 (see: Epilepsia. 2015;56:1515-1523).1 Adapted with permission.
or mortality rate can also be attributed to other factors, including the etiology of SE, the age of the patient, the patient’s overall state at presentation (coma and GCSE are predictors of poor outcome), and the length of ICU treatment.21-23 There is also no solid evidence that rapid termination of NCSE can affect prognosis independent of the effects of etiology and other factors mentioned above.24,25 One might argue that these uncertainties justify aggressive treatment of RS/SE in the ICU, but intubation, anesthesia, and other ICU interventions may be related to an even higher risk of complications and mortality than SE itself, especially NCSE.16,17,26,27

Abortive treatment of RS/SE in the inpatient setting can be divided into 3 treatment lines: first-line treatment employs fast-acting benzodiazepines, second-line treatment involves the administration of intravenous (IV) AEDs, and third-line treatment is carried out in the ICU with general anesthetics.28 Only the first-line treatment of CSE is currently supported by a high level of evidence.29 The optimal treatment for RS/SE and the sequence of administration of AEDs and anesthetic agents, especially in patients with NCSE, remains controversial.30 Despite the first 2 treatment lines, about a third of SE patients continue seizing and progress to refractory SE and about half of patients with refractory SE progress to super-refractory SE.31 This motivated experts to try drugs with no SE indication (eg, other AEDs or anesthetics, magnesium, corticosteroids, and sex hormones) and other measures, such as hypothermia, electroconvulsive therapy, transcranial magnetic stimulation, and resective surgery.32 Of these therapeutic options, adding an anti-inflammatory steroid appears to be the most practical and most promising approach for now. In the last decade, nearly 2 dozen applications of anti-inflammatory steroids (dexamethasone or methylprednisolone) in our Epilepsy Center resulted in RS/SE abortion after failure of conventional inpatient RS/SE treatment protocols. Our recent (within the last 24 months) successful abortive experiences with 4 adult RS/SE patients who received IV dexamethasone are presented here.

Case Series

All 4 patients were in consultation by our adult neurology inpatient service and all had RS/SE that was controlled with IV dexamethasone after failure of first- and second-line treatment of SE. Institutional review board review of a project summary resulted in an exemption status from institutional review board approval and continued monitoring. Demographic and clinical information are summarized in Table 2. Detailed clinical information and timelines are presented in the text for each patient. SE types, seizure types, and EEG findings are described based on the ILAE and ACNS recommended nomenclatures.1,3

Patient 1 is a 61-year-old female with mesial temporal lobe epilepsy and bilateral hippocampal sclerosis who presented with a 3-day history of delirium. She arrived in the ER mildly confused with constant eye blinking. EEG revealed generalized 2 to 3 Hz semirhythmic delta activity superimposed on rhythmic theta and alpha activity with eye blink artifacts occurring at a rate of ~1/s (Figure 1: top). The findings were consistent with NCSE without coma with impaired consciousness (SE:B2bc; Table 1) and with oculoconic status (SE:A3d; Table 1). After treatment with lorazepam 4-mg IV and levetiracetam 2000-mg IV, she was admitted to the ICU and CEEG was started. Oculoconic status ceased but NCSE persisted on levetiracetam 1500-mg IV q12h. Lacosamide 300-mg IV was loaded the next day followed by 200-mg IV q12h. On day 3, valproate 2000-mg IV was also loaded followed by 1000-mg IV q12h, but this was stopped 2 days later because of hyperammonemia. On day 4, the dose of levetiracetam was increased to 2000-mg IV q12h. She developed third-degree atrioventricular block and symptomatic bradycardia, which resolved when the dose of lacosamide was reduced to 100-mg IV q12h. Despite all these measures, NCSE persisted but third-line treatment with anesthesia was not justified since she remained awake and conversant (albeit confused). Instead, dexamethasone was started on day 5. A 10-mg IV load was administered followed by 5.2-mg IV q6h. Three days after starting dexamethasone, CEEG showed complete resolution of epileptiform activity (Figure 1: bottom); and her mental status also started to normalize. Dexamethasone was continued for 2 more days at a lower dose of 5.2-mg IV q12h before it was finally discontinued. She remained on levetiracetam and lacosamide with no seizure recurrence.

Patient 2 is a 56-year-old female with a recent history of seizures attributed to left frontal hemorrhage from head trauma 2 months prior to admission. She was taking levetiracetam 1000-mg PO q12h. She was found unresponsive and brought to the ER where she had a 60-second episode of focial to bilateral tonic-clonic seizure. Initial treatment consisted of lorazepam 4-mg IV and levetiracetam 1500-mg IV loading dose followed by 500-mg IV q12h. EEG on day 2 showed left frontal interictal sharp waves. Her mental status improved and she became less somnolent. She was seizure-free for 4 days before she had a 30-second focal clonic seizure involving the right face and hand with impaired awareness. She became inattentive and somnolent again so levetiracetam was increased to 2000-mg IV q12h. On day 5, she started having continuous right face and hand jerking and EEG showed 0.5 to 1/s lateralized periodic discharges (sharp waves) over the left hemisphere that were time-locked to the jerks (Figure 2: top). The findings were consistent with epilepsy partialis continua (EPC; SE:A3b; Table 1). Brain MRI revealed acute left temporoparietal infarction in addition to old traumatic brain lesions. After lacosamide 100-mg IV q12h was added, myoclonic jerks stopped and she became more alert. On day 9, she started having focal aware clonic seizures, which resembled the initial EPC except for lack of
The dose of lacosamide was increased to 150-mg IV q12h, but focal clonic seizures continued to occur frequently (~1/hour). Dexamethasone 10-mg IV was loaded followed by 4-mg IV q6h. After 3 days on dexamethasone, she became seizure-free (Figure 2: bottom). Dexamethasone was discontinued 25 hours after the last seizure. She remained seizure-free on levetiracetam and lacosamide.

Patient 3 is a 51-year-old male with a history of right frontal and parietal hemorrhage due to head trauma 6 months prior to admission. He had seizures in the past and was recently admitted due to tonic-clonic seizures, which was controlled with levetiracetam, lacosamide, and carbamazepine. He was discharged on these 3 AEDs, but only took levetiracetam 1000-mg PO q12h prior at home. He started exhibiting left face, arm, and leg jerks at home. On admission, EEG showed 0.5 to 1/s lateralized (left > right) periodic discharges with sharp morphology and superimposed semi-rhythmic delta activity (Figure 4: top). The findings were consistent with NCSE without coma with impaired consciousness (SE:B2bc; Table 1) with recurrent focal clonic seizures (t1 30-60 seconds). She was intubated for airway protection and propofol was started at 10-µg/kg/min IV. She was also loaded with 1500-mg IV of levetiracetam followed by 1000-mg IV q12h. Brain MRI was normal. In the ICU, she continued to have focal clonic seizures (1-2/hour) and CEEG showed persistent NCSE. Fosphenytoin 2000-mg IV was loaded followed by 150-mg IV q8h. Propofol was

### Table 2. Demographic and Clinical Summary of Patients Presenteda.

| Patient Series #, Age (in Years), and Gender | Preexisting Disorder of the Brain and Relevant PAST Medical Conditions | Refractory Seizures or Status Subtypes and Response to Conventional Therapy (A, Aborted; P, Persisted) | Conventional Hospital Therapy to Abort Seizures | Intravenous Dexamethasone Dosing Schedule | Time of Seizure Abortion With Dexamethasone |
|---------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------------|-------------------------------------------|---------------------------------|
| 1, 61/female | Temporal lobe epilepsy with bilateral mesial temporal sclerosis | Nonconvulsive status epilepticus w/o coma with impaired consciousness (P) Oculoclonic status (A) | Lorazepam, levetiracetam, lacosamide valproate | 10 mg loading dose 3 days after the first dose of dexamethasone | 10 mg q6h (3 days) 5.2 mg q6h (2 days) |
| 2, 56/female | H/o traumatic brain injury: left frontal parenchymal and subdural hemorrhage | Epilepsia partialis continua (A) | Lorazepam, levetiracetam, lacosamide | 10 mg loading dose 3 days after the first dose of dexamethasone | 4 mg q6h (3 days) |
| 3, 51/male | H/o traumatic brain injury: right frontal and parietal hemorrhage | Epilepsia partialis continua (P) | Lorazepam, levetiracetam, lacosamide | No loading dose 3 days after the first dose of dexamethasone | 4 mg q6h (3 days) |
| 4, 75/female | H/o breast cancer: no MRI evidence of structural brain lesion | Nonconvulsive status epilepticus w/o coma with impaired consciousness (P) | Propofol, levetiracetam, fosphenytoin, midazolam, lacosamide | 10 mg loading dose 4 days after the first dose of dexamethasone | 4 mg q6h (6 days) |

aWe arbitrarily defined refractory seizures as frequently-recurring (>10 episodes over 24 hours) short-duration (<30 seconds) seizures that cannot be controlled with at least one benzodiazepine and at least one non-benzodiazepine antiepileptic drug. Seizures that were immediately aborted are not included in the table.
bSee Report of the ILAE Task Force on Classification of Status Epilepticus (Epilepsia, 2015) and ILAE 2017 operational classification of seizure types (Epilepsia, 2017).
Figure 1. EEG of Patient 1. Top: generalized 2 to 3 Hz semirhythmic delta activity superimposed on rhythmic theta and alpha activity with patient delirious and perseverating consistent with NCSE and with patient blinking every second on average (see eye blink artifacts) consistent with oculoclonic status. Bottom: electrographic (and clinical as seen on video) resolution of status epilepticus 3 days after dexamethasone was added to conventional inpatient antiepileptic therapy. Display parameters: longitudinal bipolar montage (from top to bottom: left-mid-right-ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter turned on; voltage-time scale is included in the tracing.
Figure 2. EEG of Patient 2. Top: lateralized periodic discharges (sharp delta waves) over the left hemisphere time-locked to the myoclonic jerks of the right hand and face (surface EMG recorded over right face) consistent with epilepsia partialis continua. Note fluctuation of discharge rate from 1.5 to 2/s to 0.5 to 1/s. Bottom: electrographic resolution of periodic discharges 3 days after dexamethasone was added to conventional antiepileptic therapy coinciding with complete control of clinical seizures. Display parameters: longitudinal bipolar montage (from top to bottom: left-mid-right-EMG/ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter turned on; voltage-time scale is included in the tracing.
Figure 3. EEG of Patient 3. Top: 0.5 to 1/s lateralized periodic discharges (sharp/delta waves) with maximum voltage over the right frontocentral superimposed on irregular slow waves and time-locked to the myoclonic jerks of the left face, arm, and leg consistent with epilepsia partialis continua. Bottom: electrographic (and clinical as seen on video) resolution of epilepsia partialis continua 3 days after dexamethasone was added to conventional antiepileptic regimen. Display parameters: longitudinal bipolar montage (from top to bottom: left-mid-right-ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter turned on; voltage-time scale is included in the tracing.
Figure 4. EEG of Patient 4. **Top:** 1 to 2/s lateralized (left > right) periodic discharges with sharp morphology and superimposed on semirhythmic delta activity recorded while the patient was stuporous with intermittent episodes of right lower extremity jerking findings that are consistent with NCSE without coma with impaired consciousness and focal clonic seizure. **Bottom:** Persistence of left frontocentral 0.3 to 0.5/s periodic discharges approximately 5 days after dexamethasone was added and the patient was already seizure-free. **Display parameters:** longitudinal bipolar montage (from top to bottom: left-mid-right-ECG), digital filter bandpass of 1 to 70 Hz, and 60-Hz notch filter turned on; voltage-time scale is included in the tracing.
uptitrated but she became hypotensive at 40 μg/kg/min. Midazolam drip was started and burst suppression was sustained for 2 days with 60 to 80 mg/kg/min of IV midazolam. Every time midazolam was weaned off, epileptiform discharges reappeared. Lacosamide 750-mg IV q12h IV was added. CEEG showed persistent NCSE with periodic sharp waves appearing more localized over the left frontocentral region. Focal clonic seizures also started to involve the right face and arm in addition to the leg. On day 6, dexamethasone 10-mg IV was loaded followed by 4-mg IV q6h. Four days after dexamethasone was started, all clinical seizures stopped but 0.3 to 0.5/s lateralized periodic discharges persisted in EEG (Figure 4: bottom). Dexamethasone was continued for 2 more days after she stopped seizing. She remained seizure-free on levetiracetam, lacosamide, and phenytoin.

**Discussion**

Seizure control can be achieved by eliminating all factors that promote neuronal hyperexcitability and hypersynchrony. In practice, this is not always feasible in the acutely ill patient. In the inpatient setting, the general approach is to abort seizures immediately with rapidly acting AEDs, followed by maintenance therapy to prevent seizure recurrence. Unfortunately, RS/SE—seizures that persist despite conventional treatment with maximal doses of multiple AEDs—is not uncommon in the inpatient setting. Our case series shows that adding IV dexamethasone to conventional antiseizure therapy (lorazepam, levetiracetam, lacosamide, valproate, fosphenytoin, and/or anesthetic agents) can help abort RS/SE. Clinical and electrographic seizures stopped in all 4 patients 3 to 4 days after dexamethasone was started, and all patients remained seizure-free on 2 or 3 AEDs after dexamethasone was discontinued 1 to 3 days after all seizures stopped.

Inflammation plays an important role in seizure disorders. This role can be viewed from the perspective of autoimmunity, epilepsy, and pharmacoresistant seizures. The link between autoimmunity and seizure disorders is obvious in the case of autoimmune encephalitis where autoantibodies target biomolecules involved in neuronal signaling. However, even if autoimmunity is not the primary mechanism causing the seizure disorder, inflammation and immune processes may still be important in the pathogenesis of epilepsy. There is mounting evidence that inflammatory mediators released from the brain and peripheral immune cells may be involved in generating seizures (ictogenesis) and emergence of epileptic networks (epileptogenesis). Finally, it is known that some inflammatory mediators play a role, not only in generating but also in maintaining seizures, implying that these inflammatory mediators contribute to the pharmacoresistance of RS/SE.

Animal research has shown that anti-inflammatory therapy given during or shortly after SE reduces the severity of the ensuing epilepsy, as reflected by a reduction in the incidence, frequency, severity, and spread of seizures and by a decrease in brain cell loss and comorbidities. Nonetheless, we will emphasize animal experiment results indicating that brain inflammation occurs during SE and plays a role in driving seizures. Inflammatory mediators can lower the seizure threshold in animals by acting on neuronal receptors altering membrane excitability or by acting on genes inducing the transcription of proteins involved in synaptic plasticity. In rodents, various inflammatory response molecules or signaling pathways, such as the interleukins IL-1β and IL-1R1, toll-like receptor-4 (TLR4), cyclooxygenase-2 (COX-2) and prostaglandins, and complement, contribute to the onset and recurrence of stimulus-provoked seizures. Manipulation of some of these inflammatory pathways may reduce the incidence and recurrence of SE. For example, IL-1 receptor antagonists reduced the incidence, delayed the onset, and shortened the duration of pilocarpine-induced SE. Anakinra, a specific IL-1 receptor antagonist used to treat rheumatoid arthritis, caused a transient decrease in spike frequency when injected 3 hours after electrically induced SE. Antagonists of the P2X7 receptor in immune and other cells reduced the duration of acute SE. In an animal model of pharmacoresistant SE, co-administration of P2X7 receptor antagonists and benzodiazepines suppressed SE, presumably by reducing microglia activation and IL-1β levels in the forebrain. Injecting dexamethasone prior to pilocarpine in rats reduced the number of rats developing SE and, in rats that developed SE, the onset of SE was delayed and mortality was prevented; blood-brain barrier damage was also significantly reduced by dexamethasone. These results support our choice of dexamethasone (Decadron) over methylprednisolone (Solu-Medrol). In reality, we tend to choose dexamethasone for patients with no underlying autoimmunity since this drug is familiar to most physicians involved in the care of patients with RS/SE. There are, however, differences between dexamethasone, methylprednisolone, and other corticosteroids that physicians might have to consider when using anti-inflammatory steroids as adjunctive therapy for seizures.

Human RS/SE is most likely influenced by inflammatory mediators, but few studies directly address this issue. Extensive extravasation of albumin has been detected in patients who died during SE indicating disruption of the blood-brain barrier. Signs of pronounced focal inflammation, including strong IL-1β expression, intense gliosis, and minimal lymphocytic infiltration, were found in the temporal cortex resected from a patient with refractory SE. The endogenous control of brain inflammation may be inadequate during SE. Children with febrile SE have elevated serum levels of IL-1β and IL-6; and children with febrile SE have higher HMGB1 levels as well compared with controls with fever but no seizures. The cerebrospinal fluid levels of the cytokines IL-6, IL-8, and CXCL10 were much higher in patients with refractory SE due to febrile infection-related epilepsy syndromes than in
patients with other inflammatory brain disorders. The fact that adrenocorticotropic hormone (ACTH) and prednisolone are effective in West syndrome imply that inflammatory mechanisms are important in the pathophysiology of infantile spasm.

Epilepsy pharmacotherapy relies heavily on seizure prevention with AEDs, but this approach should not be exclusive. An understanding of the mechanisms in which inflammatory mediators promote the formation of epileptic circuitry can lead to novel therapies for suppressing epileptogenesis directly. A related issue in need of urgent attention is the current approach to RS/SE in the inpatient setting. Immunotherapies, such as corticosteroids, plasma exchange, intravenous immunoglobulins, rituximab, and cyclophosphamide, are, by and large, reserved for seizure disorders with underlying autoimmune mechanisms. The use of immunomodulators to control RS/SE in the typical seizure patient with no autoimmune disorder deserves investigation. Controlled studies must be conducted to determine whether broad-spectrum anti-inflammatory steroids, such as dexamethasone or methylprednisolone, can help abort RS/SE and obviate intubation and anesthesia. The case series presented here only provides anecdotal evidence for stimulating discussion and perhaps further experimental investigations. These patients were treated based on their presenting and persistent situations, not in the systematic way required for scientific evidence.

Conclusion

Despite an increase in the availability of fast-acting AEDs and anesthetic agents, aborting RS/SE in the inpatient setting can still be challenging. Multiple AEDs administered at maximal doses can fail to abort RS/SE. Because standard AED regimens may fail to abort RS/SE, and because intubation and anesthesia are not without risks, clinicians must have other options to treat RS/SE. Our case series shows that anti-inflammatory agents, in particular dexamethasone, may satisfy this need. Furthermore, our case series suggests a key role for inflammatory or immune factors in generating and perpetuating seizures, or at least drug-resistant seizures, in humans.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Our institution does not require ethical approval for reporting a case series.

Informed Consent

Informed consent for patient information to be published in this article was not obtained because this is a case series and our Ethics Committee does not require institutional review board approval.

References

1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on classification of status epilepticus. Epilepsia. 2015;56: 1515-1523.
2. Fisher RS, Cross JH, D’Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531-542.
3. Hirsch LJ, LaRoche SM, Gaspard N, et al. American Clinical Neurophysiology Society’s standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. 2013;30: 1-27.
4. Blume WT, Luders HO, Mizrahi E, et al. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia. 2001;42: 1212-1218.
5. Lowenstein DH. The management of refractory status epilepticus: an update. Epilepsia. 2006;47(suppl 1):35-40.
6. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922-930.
7. Mader EC Jr, Olejniczak PW. Epilepsy syndromes. In: Fisch BJ, ed. Epilepsy and Intensive Care Monitoring: Principles and Practice. New York, NY: Demos; 2010:119-150.
8. Sutter R, Semmlack S, Kaplan PW. Nonconvulsive status epilepticus in adults—insights into the invisible. Nat Rev Neurol. 2016;12:281-293.
9. Grillo E. Postictal MRI abnormalities and seizure-induced brain injury: notions to be challenged. Epilepsy Behav. 2015;44: 195-199.
10. Scott RC. What are the effects of prolonged seizures in the brain? Epileptic Disord. 2014;16(spec no. 1):S6-S11.
11. Jirsch J, Hirsch LJ. Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population. Clin Neurophysiol. 2007;118:1660-1670.
12. Claassen J. How I treat patients with EEG patterns on the ictal-interictal continuum in the neuro ICU. Neurocrit Care. 2009;11:437-444.
13. Cormier J, Maciel CB, Gilmore EJ. Ictal-interictal continuum: when to worry about the continuous electroencephalography pattern. Semin Respir Crit Care Med. 2017;38:793-806.
14. Unterberger I. Status epilepticus: do treatment guidelines make sense? J Clin Neurophysiol. 2016;33:10-13.
15. Shorvon S. Guidelines for status epilepticus: are we there yet? Neurocrit Care. 2012;17:1-2.
16. Marchi NA, Novy J, Faouzi M, Stähli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43:1003-1009.
17. Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656-664.
18. Holmes GL. Seizure-induced neuronal injury: animal data. Neurology. 2002;59(suppl 5):S3-S6.
19. Avdic U, Ahl M, Clugh D, et al. Nonconvulsive status epilepticus in rats leads to brain pathology. Epilepsia. 2018;59:945-958.
20. Kandratavicius L, Balista PA, Lopes-Aguiar C, et al. Animal models of epilepsy: use and limitations. Neuropsychiatr Dis Treat. 2014;10:1693-1705.
21. Claassen J, Lokin JK, Fitzsimmons BF, Mendelsohn FA, Mayer SA. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002;58:139-142.
22. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70:72-77.
23. Sutter R, Kaplan PW, Ruegg S. Outcome predictors for status epilepticus—what really counts. Nat Rev Neurol. 2013;9:525-534.
24. Adachi N, Kanemoto K, Muramatsu R, et al. Intellectual prognosis of status epilepticus in adult epilepsy patients: analysis with Wechsler Adult Intelligence Scale—Revised. Epilepsia. 2005;46:1502-1509.
25. Rossetti AO, Alvarez V, Januel JM, Burnard B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260:421-428.
26. Röschke J, Kupper K, Wittstock M, Walter U. Can treatment with anesthetic anticonvulsive drugs worsen outcome in status epilepticus [in German]? Med Klin Intensivmed Notfmed. 2018;113:108-114.
27. Kowalski RG, Ziai WC, Rees RN, et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasoressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40:2677-2684.
28. Fertlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(pt 8):2314-2328.
29. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48-61.
30. Brophy GM, Bell R, Claassen J, et al. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23.
31. Betjemann JP. Current trends in treatment of status epilepticus and refractory status epilepticus. Semin Neurol. 2015;35:621-628.
32. Vezzani A, Dingleline R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother. 2015;15:1081-1092.
33. Gaspard N. Autoimmune epilepsy. Continuum (Minneap Minn). 2016;22(1 epilepsy):227-245.
34. Barker-Haliski ML, Löschner W, White HS, Galanopoulos AS. Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy. Epilepsia. 2017;58(suppl 3):39-47.
35. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15:144.
36. Vezzani A, Auvin S, Ravizza T, Aronica E. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds. Jasper’s Basic Mechanisms of the Epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information; 2012.
37. Wang M, Chen Y. Inflammation: a network in the pathogenesis of status epilepticus. Front Mol Neurosci. 2018;11:341.
38. Vezzani A, Viviani B. Neurmodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacol. 2015;96(pt A):70-82.
39. Fourgeaud L, Boulanger LM. Role of immune molecules in the establishment and plasticity of glutamatergic synapses. Eur J Neurosci. 2010;32:207-217.
40. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011;25:1281-1289.
41. Ravizza T, Balosso S, Aronica E, Vezzani A. Brain inflammation and epilepsy. In: Rho JM, Sankar R, Strafstrom CE, eds. Epilepsy: Mechanisms, Models and Translational Perspectives. Boca Raton, FL: CRC Press; 2010.
42. Rojas A, Jiang J, Ganesh T, et al. Cyclooxygenase-2 in epilepsy. Epilepsy. 2014;55:17-25.
43. Marchi N, Fan Q, Ghosh C, et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis. 2009;33:171-181.
44. Noé FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013;59:183-193.
45. Henschall DC, Engel T. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus. Epilepsy Behav. 2015;49:8-12.
46. Fischer W, Franke H, Krügel U, et al. Critical evaluation of P2X7 receptor antagonists in selected seizure models. PLoS One. 2016;11:e0156468.
47. Marchi N, Granata T, Freri E, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One. 2011;6:e18200.
48. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician. 1998;58:443-450.
49. van Vliet EA, da Costa Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. J Neurol Neurosurg Psychiatry. 2015;96(pt A):70-82.
50. Ahluwalia HS, Polak J, Jackett R, et al. Successful surgical therapy and outcome in status epilepticus: the impact of vasoressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40:2677-2684.
51. Betjemann JP. Current trends in treatment of status epilepticus and refractory status epilepticus. Semin Neurol. 2015;35:621-628.
52. Vezzani A, Dingleline R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother. 2015;15:1081-1092.
53. Gaspard N. Autoimmune epilepsy. Continuum (Minneap Minn). 2016;22(1 epilepsy):227-245.
54. Barker-Haliski ML, Löschner W, White HS, Galanopoulos AS. Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy. Epilepsia. 2017;58(suppl 3):39-47.
55. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15:144.
56. Vezzani A, Auvin S, Ravizza T, Aronica E. Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds. Jasper’s Basic Mechanisms of the Epilepsies. 4th ed. Bethesda, MD: National Center for Biotechnology Information; 2012.
57. Wang M, Chen Y. Inflammation: a network in the pathogenesis of status epilepticus. Front Mol Neurosci. 2018;11:341.
58. Vezzani A, Viviani B. Neurmodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacol. 2015;96(pt A):70-82.
59. Fourgeaud L, Boulanger LM. Role of immune molecules in the establishment and plasticity of glutamatergic synapses. Eur J Neurosci. 2010;32:207-217.
60. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011;25:1281-1289.
61. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011;25:1281-1289.
as antiepileptogenic treatments. *Neurotherapeutics*. 2014;11: 385-400.

55. Legido A, Katsetos CD. Experimental studies in epilepsy: immunologic and inflammatory mechanisms. *Semin Pediatr Neurol*. 2014;21:197-206.

56. Clossen BL, Reddy DS. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. *Biochim Biophys Acta Mol Basis Dis*. 2017;1863: 1519-1538.

57. Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. *Epilepsia*. 2011;52(suppl 8): 53-56.

58. Reddy DS, Estes WA. Clinical potential of neurosteroids for CNS disorders. *Trends Pharmacol Sci*. 2016;37:543-561.